Dissecting the impact of tumor suppressor genes in oncogenically driven lung adenocarcinoma

Precision medicine has fundamentally changed the field of oncology and dramatically shifted the overall survival of lung cancer patients. This concept builds on the unique dependency of tumors on individual oncogenic drivers like mutant EGFR or rearranged ALK. However, co-occurring mutations can have a major impact on disease progression as well as drug response and functional models that faithfully capture these alterations remain scarce. My research goal is to dissect the relevance of co-occurring mutations in the context of oncogenically driven lung cancer to further improve the efficacy of precision medicine in these patients.